Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 18/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ERG | P11308 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16291211 | 0.82 | TACR3 (0.67) | TACR3CYP1A2CYP3A4ERGCYP2C9 | |
| SCHEMBL2553007 | 0.81 | TACR3 (1.00) | TACR3CYP1A2CYP3A4ERGCYP2C9 | |
| SCHEMBL2550879 | 0.76 | TACR3 (1.00) | TACR3CYP1A2CYP2C19 | |
| SCHEMBL2563955 | 0.74 | TACR3 (1.00) | TACR3CYP1A2CYP3A4ERGCYP2C9 | |
| Hydrochloric Acid SCHEMBL2565547 | 0.68 | TACR3 (0.57) | TACR3CDK5CDK5R1 | |
| SCHEMBL16291210 | 0.64 | TACR3 (0.65) | TACR3CYP1A2CYP3A4ERGCYP2C9 | |
| SCHEMBL2563275 | 0.63 | TACR3 (1.00) | TACR3CYP1A2CYP2C19P2RX7 | |
| SCHEMBL2555195 | 0.62 | TACR3 (0.78) | TACR3CYP1A2CYP3A4ERGCYP2C9 | |
| SCHEMBL14648845 | 0.62 | TACR3 (0.62) | TACR3CYP1A2CYP3A4ERGCYP2C9 | |
| SCHEMBL16188258 | 0.61 | TACR3 (1.00) | TACR3CYP1A2CYP3A4ERGCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140371218-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | OGEDA SA (BE) | 2014-12-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371218-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | ACKR3, BDKRB2, GPR3 | TACR3 12/4885CYP1A2 2801/4885CYP3A4 2052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.